- Is Your Family ‘CO Safe’ When Big Storms Hit?
- Bike-Linked Head Injuries Plummet for U.S. Kids, But Not Adults
- Magnets in Cellphones, Smartwatches Might Affect Pacemakers, FDA Warns
- Is Rise in Liver Damage Tied to More Drinking During Lockdowns?
- AHA News: Orthopedic Surgeon Becomes Patient After Stroke at 48
- With New Mask Guidance Comes the Challenge of Following It
- Health Highlights: May 14, 2021
- Vaping Ups Teens’ Odds for Asthma, Asthma Attacks
- Depression Even More Common With Heart Failure Than Cancer
- Can Some Movies Change Your Life? Maybe, Study Finds
Replacement Therapy Approved for Gaucher Disease
FRIDAY, Feb. 26Velaglucerase alfa for injection (VPRIV) has been approved by the U.S. Food and Drug Administration to treat a rare inherited disorder called Gaucher disease, the agency said Friday.
The disorder is caused by lack of an enzyme called glucocerebrosidase. This allows a fatty substance called a lipid to build up in the liver, spleen, bones, bone marrow and nervous system. The disorder affects only about 1 in 50,000 people, the FDA said in a news release.
The newly approved treatment replaces the lacking enzyme in people with Type 1 Gaucher disease, the disorder’s most common form. An older form of replacement therapy is in short supply, the agency said.
VPRIV’s safety and effectiveness were evaluated in clinical trials involving 82 people aged 4 and older with Type 1 Gaucher. The most common side effects reported were allergic reactions; dizziness; pain in the abdomen, joints and back; nausea, fatigue, fever, and prolonged blood clotting.
VPRIV is produced by Massachusetts-based Shire Human Genetic Therapies Inc.
More information
The U.S. National Institute of Neurological Disorders and Stroke has more about this disorder.
Source: HealthDay
